What clinicopathologic and genomic features are associated with risk for recurrence in patients with resected non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) alterations? This evidence concerns the gene EGFR and non-small cell lung carcinoma.